Group 1 - The event themed "The Future is Here: Advanced Therapies and Precision Medicine Paving the Way for Cures" successfully attracted over 70 participants from partner organizations and member units [1] - Recent advancements in therapies such as chemical drugs, CD38 monoclonal antibodies, CAR-T, and bispecific antibodies are paving the way for curing patients [3] - 2025 is identified as a critical year for precision medicine, with significant developments expected in innovative drugs, standardized diagnosis and treatment, hospital management, and medical insurance [3] Group 2 - The event featured notable speakers, including the chairman of Huimei Extreme Medical and the chairman of the organizing company, who emphasized the importance of innovation in the medical field [5] - The Vice President of the Chinese Hospital Association highlighted the achievements in cancer prevention and treatment, aiming for a 46.6% five-year survival rate for cancer by 2030 [7] - The first prescription for stem cell drugs in China was issued in June 2025, marking a significant step towards commercialization in clinical settings [7] Group 3 - The "Beijing Plan" for haploidentical stem cell transplantation has been recognized as a breakthrough in leukemia treatment, achieving a survival rate of 75%-86% [8] - The plan has been adopted globally and is included in authoritative textbooks, showcasing China's advancements in hematological malignancies [8] - The event underscored the necessity of financial support for technological innovations in the medical field, with Beijing Bank positioning itself as a key player in this ecosystem [11] Group 4 - A roundtable discussion featured experts from various fields discussing the current state and challenges of precision medicine in China, providing valuable insights for future development [13] - The event aimed to leverage the advantages of the Zhongguancun Forum membership system to foster collaboration and resource integration in advanced therapies and precision medicine [13]

Core Viewpoint - Zhongguancun Science and Technology Leasing (01601) has entered into a financing lease agreement with Henan Baichuan Changyin Environmental Energy Co., Ltd., involving a total transaction value of approximately RMB 30 million for leasing assets [1] Group 1: Financing Lease Agreement - The company will purchase leasing assets from the lessee for RMB 30 million [1] - The leasing assets consist of tank containers [1] - The lease term is set for 36 months, with total lease payments amounting to approximately RMB 32.62 million [1]

Group 1 - The company, Zhongguancun Technology Leasing (01601), announced a financing lease agreement with Henan Baichuan Changyin Environmental Energy Co., Ltd. (300614) [1] - The total transfer price for the leased asset is RMB 30 million, with a total lease payment of approximately RMB 32.6195 million over a lease term of 36 months [1] - The leased asset is a tank container [1]

天眼查商业履历信息显示，北京中关村科技发展(控股)股份有限公司，成立于1999年，位于北京市，是 一家以从事医药制造业为主的企业。企业注册资本75312.6982万人民币，实缴资本75312.6982万人民 币。公司法定代表人为许钟民。 通过天眼查大数据分析，北京中关村科技发展(控股)股份有限公司共对外投资了24家企业，参与招投标 项目6次，知识产权方面有商标信息139条，此外企业还拥有行政许可13个。 来源：金融界 金融界消息 截至2025年8月25日收盘，中 关 村（000931）报收于5.61元，上涨2.0%，换手率3.41%，成 交量25.60万手，成交金额1.42亿元。 资金流向方面，今日主力资金净流入1360.38万元，占比成交额9.56%。其中，超大单净流入1190.66万 元、占成交额8.36%，大单净流入169.72万元、占成交额1.19%，中单净流出流出1018.00万元、占成交 额7.15%，小单净流出342.38万元、占成交额2.4%。 中关村最新一期业绩显示，截至2025一季报，公司营业总收入6.16亿元、同比增长1.63%，归属净利润 1575.64万元，同比增长35.47%，扣非 ...

Core Viewpoint - The announcement highlights that Shandong Huasu Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration (NMPA) for the marketing of Succinic Acid Metoprolol raw materials, which is expected to enhance the company's market competitiveness and operational performance [1][3]. Group 1: Approval Details - The chemical raw material approved is Succinic Acid Metoprolol, with the application number CYHS2460273 and notification number 2025YS00723 [1]. - The approval indicates that the product meets the relevant requirements for drug registration as per the Drug Administration Law of the People's Republic of China [1]. Group 2: Product Background - Succinic Acid Metoprolol is a selective β1-adrenergic receptor blocker, initially developed in 1969, used clinically for treating hypertension, angina, and heart failure [2]. - There are currently 16 manufacturers listed for Succinic Acid Metoprolol raw materials, with 12 classified as "A" status and 4 as "I" status according to the CDE raw and auxiliary material registration information platform [2]. Group 3: Impact on the Company - The approval of Succinic Acid Metoprolol provides a stable raw material source for the company's ongoing research into sustained-release capsules, thereby enhancing the competitiveness of related products [3]. - The company emphasizes the importance of drug research and development, maintaining strict quality control throughout the drug development, manufacturing, and sales processes [3].

Core Viewpoint - The announcement from Zhongguancun indicates that its subsidiary, Shandong Huasu Pharmaceutical Co., has received approval from the National Medical Products Administration for the marketing application of the raw material drug Succinic Acid Metoprolol [2] Group 1 - Zhongguancun will disclose the consistency evaluation application for Naloxone Injection and the marketing application for Succinic Acid Metoprolol raw material drug by March 2024 [2] - Shandong Huasu's Succinic Acid Metoprolol raw material drug has passed the technical review by the National Medical Products Administration's Drug Evaluation Center [2] - The company has received the "Approval Notice for Chemical Raw Material Drug Marketing Application" issued by the National Medical Products Administration [2]

关于下属公司山东华素琥珀酸美托洛尔原料药获批上市的公告 共 2 页 证券代码：000931 证券简称：中关村 公告编号：2025-092 北京中关村科技发展（控股）股份有限公司 关于下属公司山东华素琥珀酸美托洛尔原料药获批上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）于 2024 年 3 月披露《关于下属公司北京华素盐酸纳洛酮注射液一致性评价申报和山东华素琥 珀酸美托洛尔原料药申报收到国家药监局<受理通知书>的公告》（公告编号： 2024-025）。 近日，公司下属公司山东华素制药有限公司（以下简称：山东华素）"琥珀 酸美托洛尔原料药"于近日通过国家药品监督管理局药品审评中心（以下简称： CDE）技术审评，并获得国家药品监督管理局（以下简称：国家药监局）核准签 发的《化学原料药上市申请批准通知书》。现将具体情况公告如下： 一、批件主要内容 化学原料药名称：琥珀酸美托洛尔 申请事项：境内生产化学原料药上市申请 受理号：CYHS2460273 通知书编号：2025YS00723 生产企业：山东华 ...

Core Viewpoint - The approval of "Succinic Acid Metoprolol API" by the National Medical Products Administration (NMPA) is expected to positively impact the company's operational performance by providing a stable raw material source for its research and development of sustained-release capsules [1] Group 1 - The company's subsidiary, Shandong Huasu Pharmaceutical Co., Ltd., has successfully passed the technical review by the NMPA [1] - The company has received the "Approval Notification for Chemical Raw Material Drug Listing Application" from the NMPA [1] - The approval is significant for the company's ongoing development of Succinic Acid Metoprolol sustained-release capsules [1]

Core Insights - The article highlights that Zhongguancun KJ has been recognized in the "2025 China Tech 50" list by Fortune, showcasing its comprehensive capabilities in the vertical large model sector from technology research and development to platform application and industrial implementation [2] - The recognition reflects Zhongguancun KJ's strong technological innovation and its pioneering role in integrating artificial intelligence with the real economy [2] Company Strategy - Since 2023, Zhongguancun KJ has strategically focused on large models, proposing a "platform + application + service" three-tier engine strategy, which has gained wide industry recognition and is seen as a key paradigm for driving industrial intelligence upgrades [5] - The company has developed a competitive technology product system based on self-developed cutting-edge technologies such as artificial intelligence, large models, smart audio and video, and blockchain [5] Industry Impact - Zhongguancun KJ has created a comprehensive product matrix centered around its large model platform, covering various scenarios such as intelligent customer service, marketing, operations, and office solutions, supporting key industries like finance, public administration, industrial manufacturing, automotive, retail, and Chinese enterprises going global [5][6] - The company has established multiple industry benchmark cases, including collaborations with Ningxia Jiaojian for a transportation infrastructure large model and with China Shipbuilding Group for a shipbuilding industry large model [6] Market Position - As of now, Zhongguancun KJ has provided services to over 2,000 leading enterprises, including 50% of China's top 100 banks and 70% of provincial and municipal public security agencies [6] - The company is the only one to leverage its large model advantages to be listed in the "2024 Hurun China AI Companies 50" and has been included in the Hurun Global Unicorn List for five consecutive years [6] - According to IDC's "China Intelligent Customer Service Market Share Report (2024)," Zhongguancun KJ ranks fourth in the intelligent customer service sector and first among vertical large model vendors [6] Future Outlook - The company aims to continue deepening its "platform + application + service" strategy, focusing on vertical large models to provide Chinese solutions for global industrial intelligence [6]

证券日报网讯 8月20日晚间，中关村发布公告称，公司2025年第五次临时股东会审议通过了《关于山东 中关村为山东华素向交通银行申请4，600万元融资授信提供担保的议案》等多项议案。 （文章来源：证券日报） ...